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Abstract
Background: Primary high risk (hr)HPV screening will be introduced in The Netherlands in January 2017. Our aim
was to determine the hrHPV prevalence in the Dutch cervical cancer screening population (DuSC study).
Methods: A total of 12,113 residual PreservCyt cervical samples from the Dutch population based cytology
screening program were rendered anonymous, randomized and tested for hrHPV using 3 HPV assays on their
respective automated platforms: QIAGEN’s digene® HC2 HPV DNA Test® (HC2, signal amplification), Roche Cobas®
HPV test (DNA amplification) and Hologic Aptima® HPV Test (RNA amplification). To determine the agreement
between results generated using the different assays, pair wise comparison of the systems was performed by
determining kappa coefficients.
Results: The selected samples were representative for the population based screening program with respect
to age distribution and cytology classification.
HrHPV prevalences found were: 8.5% for HC2 (n = 959), 8.1% for cobas (n = 919) and 7.5% for Aptima (n = 849),
resulting in a mean hrHPV prevalence of 8.0 ± 0.5%. Although the hrHPV prevalences of the different assays are in
the range of 8%, there was a significant difference in prevalence for the HC2 vs. Aptima assay (p-value = 0.007).
A clear age dependency was found, with an hrHPV prevalence ranging from 18.7 ± 1.2% in women 29-33 years of
age to 4.2 ± 0.2% in women 59–63 years of age. Furthermore, a correlation between hrHPV prevalence and severity
of cytology was observed, ranging from 5.5 ± 0.4% in normal cytology to 95.2 ± 1.7% in severe dysplasia.
Indeed, kappa coefficients of 0.77, 0.71 and 0.72 (HC2 vs cobas, cobas vs Aptima and Aptima vs HC2, respectively)
indicated substantial agreement between the results generated by the different systems. However, looking at the
hrHPV positive samples, only 48% of the samples tested positive with all 3 assays.
Conclusions: A hrHPV prevalence of 8% was found in this unselected population based screening cohort independently
of using HC2, Aptima or cobas. This prevalence is higher than the previously reported 4–5% (POBASCAM and
VUSA-Screen trials). Furthermore, the complete automated hrHPV detection workflow solutions from QIAGEN,
Roche, and Hologic were successfully used and will be valuable for reliably implementing high throughput
hrHPV testing in cervical cancer screening.
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Background
Since the 1980s, a well monitored cervical cancer screen-
ing program has been employed in The Netherlands,
which was further improved by implementing high risk
human papillomavirus (hrHPV) triage in 2006. Women
aged 30–60 years are invited to undergo screening once
every five years. The screening consists of a Pap smear
(liquid based cytology) which is examined by microscopy
for the presence of abnormal cells. Depending on the out-
come: 1) referral takes place to the next screening round
(no abnormalities), 2) molecular triage testing takes place
for the presence of hrHPV (equivocal or mild abnormal-
ities) and 3) immediate referral to the gynaecologist takes
place (moderate or severe abnormalities). When hrHPV is
present in cases of equivocal or mild abnormalities, gynae-
cologist referral takes place; when hrHPV is absent the
patient is invited for follow up cytology testing in 6 months.
Although the current screening program has been
shown to be effective in reducing the incidence of
cervical cancer and the number of cervical cancer
related deaths, cervical cancer is still substantially missed
and there is potential for improvement [1]. Therefore,
based on a recommendation by the Dutch health
council, primary cytology screening will be replaced by
primary hrHPV screening.
Primary hrHPV screening with molecular testing has
been shown to be more sensitive in detecting high-grade
cervical intraepithelial neoplasia (CIN2-3) [2]. This
higher sensitivity makes it possible to reduce the number
of screening rounds. In case of the Dutch situation, the
number of screening rounds will decrease from 7 to 5
(30, 35, 40, 50 and 60 years) [1–3]. However, due to
lower clinical specificity, hrHPV testing might lead to
the detection of clinically irrelevant hrHPV infections
leading to increased referral to the gynaecologist and
unnecessary colposcopy [4]. Nowadays many hrHPV tests
are commercially available. These assays differ signifi-
cantly with regard to analytical and clinical sensitivities
and specificities and are therefore not all suitable for use
in population based screening. Therefore, in 2009 inter-
national guidelines were established for human papilloma-
virus DNA test requirements for primary cervical cancer
screening in women 30 years and older [5, 6].
Modeling has indicated that the new Dutch cervical
cancer screening program design, based on primary
hrHPV testing, will prevent around 11% (n = 75 out of
700) more of annual Dutch cervical cancer cases and 7–9%
(n = 18 out of 200–250) more of annual cervical cancer
related deaths in the Netherlands, whilst maintaining the
costs of the current screening program [1]. With regard to
the cost-effectiveness of such a program, hrHPV prevalence
within the screening cohort, amongst other costs of
the hrHPV test, is of pivotal importance. Based on
the POBASCAM and VUSA screen studies, the Dutch
health council stated an overall hrHPV prevalence of
4–5% within the population of the cervical cancer
screening program [2, 7].
Several large studies have been performed to date
regarding the efficacy of primary hrHPV screening,
hrHPV prevalence and comparison of hrHPV detection
technologies [8–12]. The number of samples in these
studies ranged from 6,000 to over 44,000 and were
derived from (a selection of ) women from different
cervical cancer screening cohorts. The employed hrHPV
detection assays were GP5+/6 + PCR-EIA, Hybrid
Capture 2, Aptima and cobas which yielded hrHPV
prevalences ranging from 3.6% to 16.2%.
None of these studies, however, were performed in a
setting exactly simulating the current (Dutch) population
based screening program but often in a well defined study
population. Additionally, no studies have yet been con-
ducted using the currently available, fully automated – in-
cluding de- and recapping and processing of primary
sample containers - hrHPV testing systems capable of
processing the large sample numbers involved in a pri-
mary screening setting. Our aim was therefore to deter-
mine hrHPV prevalence in the DuSC (Dutch screening
comparison) hrHPV study, investigating a cohort repre-
sentative for the Dutch population based screening cohort
using fully automated hrHPV solutions that are currently
commercially available and use hrHPV detection assays
that were approved by the Dutch Society of Pathology and
International guidelines for HPV testing [5, 6, 13].
Methods
Study population and design
Residual ThinPrep® PreservCyt® Collection Medium
(Hologic, Marlborough, MA) with cervical samples from
the Dutch population based cytology screening program
from the Eastern part of the Netherlands were used. In
total, 12,113 consecutive samples from August 2013 to
July 2014 were included from women with a “primary
invitation” for the following screening round, thereby
excluding follow-up samples. Age distribution was
matched with that of the Dutch screening population
based on the number of Dutch women in each age
group in combination with the attendance rates per age
group [14]. Age groups were based on the invitation
schedule for the screening program and defined as
follows: 29–33, 34–38, 39–43, 44–48, 49–53, 54–58 and
59–63 years of age. Because all included samples were
derived from the primary screening population, matched
age distribution based on the actual intake of the Dutch
screening program, was expected to also result in a
representative distribution of cytology classification.
Following inclusion, the samples were randomized, and
rendered anonymous using barcodes randomly gener-
ated by the employed Access database. The bar-coded
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containers were suitable for further automated sample
handling. Dutch regulation does not allow use of residual
samples from the screening program aged <4 months.
Therefore, minimal sample age at time of testing was
4 months and ranged up to 12 months. Consequently, all
included samples exceeded the manufacturers’ storage
recommendation of 3 months. Further storage conditions
were as recommended by the manufacturer.
All included samples were tested for hrHPV using 3
fully automated testing solutions – from primary sample
processing to interpretation of results - that are
currently available and use hrHPV tests approved by the
Dutch Society of Pathology (NVVP [15]) and inter-
national guidelines for hrHPV testing [5, 6, 13]. These
were: the digene HC2 High-Risk HPV DNA Test® (HC2;
Qiagen, Gaithersburg, MD), the cobas® HPV Test (cobas;
Roche Diagnostics, Pleasanton, CA) and the Aptima®
HPV Test (Aptima; Hologic, San Diego, CA). Specifica-
tions of each test are depicted in Table 1.
Dedicated laboratory staff was trained by all 3 manu-
facturers and certified to perform the standardized
protocol for each system. A rotation scheme was
employed resulting in different testing orders (HC2-
cobas - Aptima, cobas-Aptima-HC2, Aptima-HC2-cobas
etc.) to prevent an influence on test performance caused
by the order in which the samples were analyzed by the
different hrHPV workflows.
digene® HC2 High Risk HPV DNA Test® (HC2)
The HC2 solution uses the digene® HC2 High Risk HPV
DNA Test® (QIAGEN, Gaithersburg, MD), which is
based on signal amplification using RNA probes to
target the entire hrHPV genome. Samples were placed in
the M1 decapper system where barcode identification,
homogenization, decapping/recapping and sample trans-
fer to a bar-coded tube took place. Subsequently,
automated sample preparation of cervical cells was
performed using the QIAsymphony DSP HPV Media Kit
in combination with the QIAsymphony. Resulting
sample extracts were tested for hrHPV using the digene®
HC2 High-Risk HPV DNA Test® with the Rapid Capture
System. Automated amplified chemiluminescent signal
detection and results reporting (hrHPV positive: relative
light unit per cut off value (RLU/CO) ≥1.0; hrHPV nega-
tive RLU/CO < 1.0) was performed using the DML3000
luminometer. All steps were performed according to the
manufacturer’s protocols.
cobas® HPV Test (cobas)
The cobas® HPV Test from Roche (Roche Diagnostics,
Pleasanton, CA) is a real time PCR based assay targeting
the hrHPV L1 gene and the human ß-globin gene as an
internal control. Uracil N-glycosylase (UNG) and dUTP
are utilized to eliminate possible amplicon carryover.
After barcode identification, homogenization and decap-
ping of the PreservCyt vials using the p480 instrument,
the samples were transferred to the x480 system for
DNA extraction and real time PCR setup using the Sam-
ple Preparation Kit (c4800 SMPL PREP) and Liquid
Cytology Preparation Kit (c4800 LIQ CYT). Samples
were homogenized again by automatic pipetting prior to
extraction. Processed sample vials were transferred back
to the p480 system for recapping. Amplification, detec-
tion and hrHPV typing (types 16, 18 and 12 “other”
hrHPV types) by real time PCR and results reporting
(hrHPV positive: Cp value <40.0 for hrHPV 18 and 12
other genotypes and Cp-value <40.5 for hrHPV 16;
hrHPV negative Cp value >40 and >40.5, respectively)
was performed using the z480 in combination with the
HPV Amplification/Detection Kit (c4800 HPV AMP/
DET). All steps were performed according to the manu-
facturer’s protocols.
Aptima® HPV Test (Aptima)
The Aptima® HPV Test (Hologic/Gen-Probe, San Diego,
CA) relies on mRNA amplification targeting the E6/E7
genes. Sample identification, homogenization, decap-
ping/recapping and transfer to a bar-coded Aptima tube
with pierceable cap was done using the Tomcat system.
The Aptima tube was transferred to the Panther system
for specific capture of hrHPV E6/E7 mRNA transcripts
by oligomer coated magnetic particles, transcription
Table 1 Overview of the HC2, cobas and Aptima test specifications and accompanying automated testing solutions
Assay Nr. of devices HrHPV types detected Target gene Detection technology Input volume Dead volume Control
HC2 4 16/18/31/33/35/39/45/
51/52/56/58/59/68
Entire hrHPV
genome (DNA)
Nucleic acid hybridization
assay with signal
amplification
3.0 mL 5.0 mL Process control for
each sample batch
cobas 3 16/18/31/33/35/39/45/
51/52/56/58/59/66/68
L1 (DNA) Real time Polymerase
Chain Reaction
0.25 mL 0.5 mL ß-globin for process
validity of individual
sample and input
sufficiency
Aptima 2 16/18/31/33/35/39/45/
51/52/56/58/59/66/68
E6/E7 (RNA) Transcription Mediated
Amplification
0.4 mL 5.0 mL Spiked internal control
for process validity of
individual sample
HC2 Hybrid Capture 2
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mediated amplification, detection and results reporting
(hrHPV positive: RLU/CO ≥ 0.5; hrHPV negative RLU/
CO < 0.5) using the Aptima HPV assay. The assay incor-
porates a spiked internal control monitoring mRNA
capture, amplification and detection, as well as operator
and instrument error. When sufficient remnant sample
was available (volume used 0.4 mL, dead volume 5 mL),
genotyping (types 16 and 18/45) of hrHPV positives was
subsequently performed using the Aptima® HPV 16
18/45 Genotype Assay. All steps were performed ac-
cording to the manufacturer’s protocols.
Checkerboard
To exclude a significant impact of sample contamination
on the hrHPV prevalence found in our study, we per-
formed a checkerboard experiment with all three systems.
Ninety-four residual PreservCyt samples from our rou-
tine hrHPV diagnostics (hrHPV triage testing) with a
high hrHPV viral load were pooled to a volume of 1.4 L.
This pool was mixed thoroughly and aliquoted in 3 sets
of 44 empty PreservCyt containers in portions of 8 mL
per container. Each set was designated to 1 hrHPV test-
ing system and alternately tested with 44 containers with
clean PreservCyt solution. Testing of these checkerboard
samples was performed as with diagnostic samples, start-
ing from the processing of the cervical scrape to (signa-
l)amplification and interpretation of results.
To ensure that this pool contained a sufficient amount
of hrHPV, the Cp value was determined with cobas and
compared to the Cp values of all hrHPV positives
included in the study.
Statistical analysis
The overall agreement for each combination of 2 hrHPV
tests was determined by calculation of Cohen’s
Unweighted Kappa coefficient (ĸ-coefficient). An agree-
ment was considered to be substantial with a ĸ-coeffi-
cient of ≥0.6 [16]. Inter-assay and pair wise agreements
were calculated as the total number of samples in a
group that were hrHPV positive on at least one of the
systems compared, divided by the number of samples
that were hrHPV positive on all compared systems.
Results
Study population
A total of 12,113 residual PreservCyt cervical samples
were randomized, rendered anonymous and included
from the Dutch population based cytology screening
program (district East).
Sample volumes used per system were 0.25 mL,
3.0 mL and 0.4 mL for cobas, HC2 and Aptima, respect-
ively. Dead volumes per system were 0.5 mL for cobas,
5.0 mL for HC2 and 5.0 mL for Aptima. The total
sample volume required therefore amounted to 8.65 mL
(3.65 mL used and 5.0 mL dead volume). As a result,
sufficient volume was available for 11,755, 11,917 and
11,659 samples to be tested with HC2, cobas and
Aptima, respectively. Results were considered invalid in
cases that the reporting software flagged a sample result
with “error” or “invalid”. Underlying reasons for such
flags could not be further investigated due the way the
systems generated the respective output files but are for
example technical run errors (affecting an entire run or
a large part of a run), inhibition, sampling errors due to
clotting of pipet tips etc. For each assay, a number of
these invalid results were found of which the
correspondent samples were retested: HC2 n = 670,
cobas n = 512 and Aptima n = 443, which was successful
in n = 665, n = 433 and n = 436 samples, respectively. In
n = 5, n = 79 and n = 7 samples, results remained invalid.
The substantial difference in initial invalids versus repeat
invalids can be largely explained by the fact that in the
case of a technical run error, simply repeating the run
resulted in valid results for the respective sample set. In
total, from 11,333 out of 12,113 samples, hrHPV analysis
generated valid results on all 3 systems (Fig. 1). All
further analyses were performed on the sample group
that could be tested by all three assays. Distribution of
age and cytology classification of this group were
checked and found to be identical the Dutch screening
population (see Tables 2 and 3).
HrHPV prevalence
Performing the analysis based on the group of samples
tested by all 3 systems (n = 11,333), hrHPV prevalences
found were 8.5%, 8.1% and 7.5% for HC2, cobas and
Aptima, respectively. Overall prevalence was found to be
8.0 ± 0.5%. Because of this rather low deviation, the over-
all or mean hrHPV prevalence of the 3 assays is consid-
ered to more closely resemble the “true” prevalence.
Therefore, the overall hrHPV prevalence is presented
throughout the manuscript, unless indicated otherwise.
If the cumulative hrHPV prevalences for the entire
cohort, i.e. all age groups and all cytology classes, were
determined based on the maximum amount of samples
analyzed with each assay (HC2 n = 11,755; cobas n =
11,917; Aptima n = 11,659) these were found to be 8.5%,
8.1% and 7.6%, respectively. Resulting in no statistical
significant difference when compared to the group of
samples tested by all 3 systems.
The rotation scheme used to prevent an influence on
assay performance by the order in which the samples were
analyzed by the different hrHPV workflows, resulted in
hrHPV prevalences of 8.0–8.9%, 7.6–8.6% and 7.0–7.9%
for HC2, cobas and Aptima, respectively, and were not
significantly different within a particular assay (p-values
range from 0.25–0.28) and differences observed are due to
different age distribution of the subgroups.
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For each hrHPV assay, the hrHPV prevalence was also
determined per age group (Fig. 2, Table 2) and Pap class
(Fig. 3, Table 3).
The hrHPV prevalence decreased with an increasing age
of the women involved, from 18.7 ± 1.2% in women aged
29–33 years to 4.2 ± 0.2% in women 59–63 years of age.
As for severity of cytology, a correlation was also observed
with hrHPV prevalence, ranging from 5.5 ± 0.4% in nor-
mal cytology to 95.2 ± 1.7% in severe dysplasia.
Checkerboard
The hrHPV pool used for the checkerboard generated
mean Cp values using cobas of 23.83 ± 0.5, 25.96 ± 0.79
and 23.14 ± 0.86 for hrHPV16, hrHPV18 and “other”
hrHPV types, respectively. When compared to the Cp
values of all hrHPV positive samples included in our
study, the hrHPV concentration in the pool is found to be
representative for 12.6%, 15.7% and 12.6% of the most
highly positives study samples containing hrHPV16,
hrHPV18 and “other” hrHPV types, respectively. All 44
samples containing clean PreservCyt solution generated a
hrHPV negative result with the HC2, cobas and Aptima
system, therefore no contamination was observed.
HrHPV assay comparison
Kappa-coefficients of each combination of 2 hrHPV tests
were based on the number of samples that generated
results using the 3 systems (n = 11,333) and were as fol-
lows: HC2 vs cobas 0.77; cobas vs Aptima 0.71; and
Aptima vs HC2 0.72.
Fig. 1 Flowchart of included sample numbers. Number of valid results vs invalid results per assay and with all 3 assays. Invalid may be due a technical
run error, inhibition, sampling error etc
Table 2 Age distribution of included patients of which test results of all 3 assays are available (n = 11,333).
Age (years) Included
samples (N)
Age distribution
of tested cohort
(DuSC)
Age distribution of
Dutch screening
population
HC2 hrHPV
prevalence
%(N)
cobas hrHPV
prevalence
%(N)
Aptima hrHPV
prevalence
%(N)
Overall hrHPV
prevalence
29–33 1,191 10.5% 10.5% 19.1% (228) 19.7% (235) 17.3% (206) 18.7 ± 1.2%
34–38 1,317 11.6% 11.7% 11.7% (154) 11.5% (152) 10.6% (140) 11.3 ± 0.6%
39–43 1,775 15.7% 16.3% 9.0% (159) 8.0% (142) 7.3% (130) 8.1 ± 0.9%
44–48 1,928 17.0% 16.9% 7.7% (148) 7.1% (137) 6.3% (122) 7.0 ± 0.7%
49–53 1,870 16.5% 16.4% 6.3% (117) 5.4% (101) 5.4% (101) 5.7 ± 0.5%
54–58 1,703 15.0% 14.7% 5.4% (92) 5.0% (86) 4.9% (84) 5.1 ± 0.3%
59–63 1,549 13.7% 13.6% 3.9% (61) 4.3% (66) 4.3% (66) 4.2 ± 0.2%
Total (N) 11,333 959 919 849
Number of included samples per age group and age distribution of study cohort vs age distribution of the Dutch screening program; and hrHPV prevalences per
assay and overall mean
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A total of 1,288 samples were found to be hrHPV posi-
tive with at least one system, of which 48.4% (n = 623) was
hrHPV positive in 3 out of 3 systems, 15.0% (n = 193) in 2
out of 3 systems and 36.6% (n = 472) in 1 out of 3 systems
(Fig. 4). Mean cobas Cp values generated in these groups
were Cp 28.6 (HC2, Aptima and cobas), 34.0 (HC2 and
cobas) and 35.7 (Aptima and cobas) and Cp 37.9 (single
positives only found by cobas), respectively (Fig. 4). Inter--
assay agreement ranged from 65.7% in women aged 29–
33 years to 31.8% in women 59–63 years of age (Table 4).
For severity of cytology the inter-assay agreement ranged
from 36.2% in Pap 1 to 91.8% and 100% in Pap 3b and 4,
respectively (Table 4). Of the hrHPV positive samples with
abnormal cytology (Pap 2/ASC-US and higher), 83.8% was
found to be positive in 3 out 3 systems, whereas 7.2% was
hrHPV positive in 1 out of 3 systems. On the contrary and
as expected, of the hrHPV positive samples with normal
cytology (Pap 1), 36.2% and 46.7% were found to be
hrHPV positive in 3/3 and 1/3 systems, respectively.
Agreement of hrHPV positives of the Aptima assay,
detecting mRNA, when pair wise compared to cobas
and HC2, both detecting DNA, was 58.0% (n = 649) and
58.7% (n = 669), respectively. This pair wise agreement
was 65.6% (n = 744) for cobas vs. HC2.
In total, 609 of the samples found hrHPV positive by
both cobas as well as Aptima could be genotyped by the
typing assays of both manufacturers. The outcome of
genotyping of hrHPV16, 18, 18/45 and “other” is
depicted in Table 5.
Prevalence of hrHPV16 was 34.0% (n = 207) in cobas
and 30.7% (n = 187) in Aptima, whereas hrHPV18 and
hrHPV18/45 were found in 10.5% (n = 64) and 11.0%
Table 3 Pap class distribution of included patients of which test results of all 3 assays are available (n = 11,333).
Pap class Bethesda
classification
Included
samples
(N)
Pap class distribution
of tested cohort
(DuSC)
Pap class distribution
of Dutch screening
populationa
HC2 hrHPV
prevalence
%(N)
cobas hrHPV
prevalence
%(N)
Aptima hrHPV
prevalence
%(N)
Overall hrHPV
prevalence
0 - 191 1.7% 1.7% 6.8% (13) 5.2% (10) 4.2% (8) 5.4 ± 1.3%
1 Normal 10,639 93.9% 93.6% 5.8% (620) 5.7% (609) 5.1% (545) 5.5 ± 0.4%
2 ASC-US 314 2.8% 3.0% 47.8% (150) 41.1% (129) 39.5% (124) 42.8 ± 4.4%
3a1 LSIL 71 0.6% 0.7% 91.5% (65) 85.9% (61) 84.5% (60) 87.3 ± 3.7%
3a2 HSIL (moderate) 50 0.4% 0.4% 94.0% (47) 94.0% (47) 94.0% (47) 94.0 ± 0.0%
3b HSIL (severe) 62 0.5% 0.6% 95.2% (59) 93.5% (58) 96.8% (60) 95.2% ± 1.7%
4 CIS/AIS 6 0.01% 0.0% 83.3% (5) 83.3% (5) 83.3% (5) 83.3 ± 0.0%
Total (N) 11,333 959 919 849
Number of included samples per Pap class and Pap class distribution of study cohort vs Pap class distribution of the Dutch screening program; and hrHPV
prevalences per assay and overall mean
Pap 0 = sample inadequate for cytology
aBased on the Dutch national pathology registry (PALGA database)
ASC-US Atypical Squamous Cells of Undetermined Significance, LSIL Low-grade Squamous Intraepithelial Lesion, HSIL High-grade Squamous Intraepithelial Lesion,
CIS Carcinoma in situ, AIS Adenocarcinoma in situ
Fig. 2 HrHPV prevalence vs. age for HC2, cobas and Aptima. Mean hrHPV prevalence per age group conform the Dutch cervical cancer screening
program for all cytology classifications. HC2 = Hybrid Capture 2
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(n = 67) of typed cases, respectively. In 78.2% (n = 476),
cobas typing yielded “other” hrHPV genotypes, whilst
Aptima typing suggested that hrHPV genotypes other
than 16 and 18/45 were present in 60.8% (n = 370).
Discussion
HrHPV prevalence
The presented study, i.e. DuSC study, is the first investi-
gating hrHPV prevalence in a setting representative for
the Dutch population based cervical cancer screening
program, without any selection of women, and utilized
the most recently introduced, fully automated hrHPV
testing systems as would be used when primary hrHPV
screening is implemented. Cumulative hrHPV preva-
lences for HC2, cobas and Aptima were in the same
range and, based on the sample group yielding results
using all 3 assays (n = 11,333), resulted in a mean hrHPV
prevalence of 8.0 ± 0.5%. As expected, a correlation was
found between hrHPV prevalence and the age of the in-
volved women as well as the Pap class (Figs. 2 and 3),
which confirmed the reliability of the blinded hrHPV
testing. The hrHPV prevalence in our study population
decreased with an increasing age, and was higher when
severity of cervical dysplasia increased. The hrHPV
prevalence observed in cytological carcinoma in situ
(Pap 4) was lower than that of Pap 3a1, 3a2 and 3b,
however, the number of samples in the Pap 4 group was
too low to be representative (n = 6).
The detected hrHPV prevalence is significantly higher
than the 4–5% stated by the Dutch Health Council [1].
The prevalence stated by the Dutch Health council was
based on data from the POBASCAM and VUSA screen
studies [2, 7]. These studies however, were not designed
to determine hrHPV prevalence in the Dutch population
based screening setting, but were conducted to evaluate
the effectiveness of different triage algorithms (VUSA
screen) and primary hrHPV screening (POBASCAM).
For example, in both these studies in contrast to our
DuSC study, a number of women were excluded from
enrollment when they had abnormal cytology or a CIN
lesion within the preceding 2 years, most likely resulting
in a selection bias. In the setting of the Dutch screening
program, women having either equivocal or mild cer-
vical dysplasia (Pap 2/3a1) on such a previous smear
would not have been excluded, but would have actually
been invited for follow-up after 6 months. This will in-
crease the hrHPV prevalence in the screening cohort by
0.5–1% and partly explains the difference in prevalence
Fig. 3 HrHPV prevalence vs. Pap class for HC2, cobas and Aptima. Mean hrHPV prevalence per Pap class for all ages. HC2 = Hybrid Capture 2.
ASC-US = Atypical Squamous Cells of Undetermined Significance; LSIL = Low-grade Squamous Intraepithelial Lesion; HSIL = High-grade Squamous
Intraepithelial Lesion; CIS = Carcinoma in situ; AIS = Adenocarcinoma in situ
Fig. 4 Inter-assay agreement between HC2, cobas and Aptima. Each
proportion was calculated based on the total number samples
found hrHPV positive (n = 1,288) in at least one of the assays
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when compared to this study. Other explanations for the
remaining difference in hrHPV prevalence might be a
cohort effect, the fact that POBASCAM and DuSC used
different hrHPV assays and/or technical issues as is for
example the case in the POBASCAM where crude cell
extracts are used instead of purified DNA. Although a
different age distribution of the population tested could
also be an explanation for the difference in hrHPV
prevalence, the women in POBASCAM were in fact
younger than in DuSC, which would result in a higher
instead of lower hrHPV prevalence in POBASCAM.
When comparing our hrHPV prevalence data to other
studies published investigating population based screen-
ing cohorts, also higher hrHPV prevalence rates were
found. Although performed in a population of different,
predominantly Canadian, geographical origin and a
somewhat different age distribution, hrHPV prevalence
found in the population based HPV FOCAL study was
similar in women ≥30 years of age with 7.2% and 6.9%
for cobas and HC2, respectively [9, 17]. In the ATHENA
trial, when excluding patients <30 years, overall hrHPV
prevalence found was 8.4% (10.5% including women 25–
29 years) [12]. In women from the Danish cervical can-
cer screening program, the hrHPV prevalence was even
higher: 9.4% for Aptima, 11.7% for HC2 and 16.2% for
cobas [18]. As earlier described, the hrHPV prevalences
found in our study with the 3 different testing solutions
were in the same range, although the hrHPV prevalence
found by the Aptima assay was found to differ signifi-
cantly when compared to HC2 (7.5% vs 8.5%, respect-
ively; p-value 0.007). This suggests that with respect to
hrHPV prevalence, the performance of all three of the
hrHPV tests employed in our study and using fully auto-
mated systems, are similar. Additional performance
comparison on several technical aspects and the degree
of user friendliness per system is not within the scope of
this study, but will be described elsewhere (manuscript
in preparation).
In theory, the higher than expected hrHPV prevalence
found in our study could be influenced by false positive
results generated as a result of sample handling; however
this is not the case since checkerboard experiments
showed no cross contamination between samples. In
addition, an influence on test performance caused by the
order of hrHPV systems in which the samples were ana-
lyzed was ruled out, since samples were randomly
assigned to a particular sequence of the 3 hrHPV testing
solutions. These different subsets yielded similar hrHPV
prevalences, also indicating no significant contamination
in a specific testing solution.
Moreover, because of the retrospective nature of this
study, sample ages ranged from 4 to 12 months meaning
all included samples exceeded the manufacturers’ storage
recommendation of 3 months. However, no substantial
differences in hrHPV prevalence were observed when
comparing different subsets composed of these various
sample ages, suggesting no significant effect of sample
age on assay performance. This is supported by the fact
that repeat analysis of similarly stored samples (n = 153)
previously tested for routine hrHPV diagnostics (hrHPV
triage) using all three hrHPV detection systems, yielded
a concordance of 85% with results previously found and
most discrepancies were, as expected, found in weak
hrHPV positive samples (data not shown). It should be
noted that samples from such a triage setting may har-
bor a relatively high hrHPV viral load in comparison to
screening samples which possibly affected the outcome
of stability testing. Therefore an effect on test perform-
ance using residual samples, instead of prospective
hrHPV testing, cannot be fully excluded. If such an ef-
fect would be present, our study design might even lead
to underestimation of the hrHPV prevalence due to
DNA/RNA degradation in stored residual samples.
Table 4 Inter-assay agreement (number of samples positive in
all 3 hrHPV assays; total n = 623) for each age group and
cytology classification
Age group Inter-assay
agreement
% (N)
Pap class Bethesda
classification
Inter-assay
agreement
% (N)
29–33 65.7% (180) 0 - 26.3% (5)
34–38 52.0% (105) 1 Normal 36.2% (339)
39–43 51.0% (103) 2 ASC-US 73.4% (113)
44–48 41.7% (86) 3a1 LSIL 90.8% (59)
49–53 47.7% (72) 3a2 HSIL
(moderate)
95.8% (46)
54–58 29.5% (43) 3b HSIL
(severe)
91.8% (56)
59–63 31.8% (34) 4 CIS/AIS 100% (5)
Total (N) 623 623
Pap 0 = sample inadequate for cytology
ASC-US Atypical Squamous Cells of Undetermined Significance, LSIL Low-grade
Squamous Intraepithelial Lesion, HSIL High-grade Squamous Intraepithelial
Lesion, CIS Carcinoma in situ, AIS Adenocarcinoma in situ
Table 5 Genotyping outcome from samples positive for hrHPV by cobas and Aptima, N(%)
Assay hrHPV 16 hrHPV 18 hrHPV 18/45 Other hrHPV types Total genotyped
cobas 207 (34.0) 64 (10.5) NA 476 (78.2) 609
Aptima 187 (30.7) NA 67 (11.0) 370 (60.8)a 609
NA not applicable
aBased on the combination of a positive hrHPV test and the absence of hrHPV16 and 18/45
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So based on hrHPV data presented in this DuSC
study, it is realistic to conclude that the hrHPV preva-
lence in the Dutch population based screening cohort is
higher than previously reported, and that hrHPV preva-
lences from POBASCAM and VUSA-screen are under
representing the hrHPV prevalence in the current
general population. An higher hrHPV prevalence could
lead to an increased referral to the gynecologist and
unnecessary colposcopy [3], influencing the health
economics of the screening program. Besides the hrHPV
prevalence, also other factors such as costs of hrHPV
test and screening organization (invitation, logistics, etc)
are of major importance. Furthermore, it is very import-
ant to have good quality cytology and standardized
criteria to circumvent unnecessary referral to colposcopy.
HrHPV assay comparison
A substantial agreement between the 3 different hrHPV
tests used, was found (kappa coefficients ranged from
0.71 to 0.77 when comparing each combination of 2
hrHPV tests). However, despite this good concordance
of 3 assays all fulfilling the international guidelines for
primary hrHPV screening, a significant number of dis-
crepancies were observed. This finding is in line with
several previous studies [19–25]. Because of the large
number of hrHPV negatives, strongly influencing ĸ-coef-
ficient and therefore overall agreement, the inter-assay
agreement should also be determined based on a
comparison of the hrHPV positive samples (Fig. 4).
Approximately half (48.4%; n = 623) of the positive
hrHPV samples (n = 1,288) generated positive results in
all 3 systems. Inter-assay agreement in our study was
found to decrease with an increasing age of the women
involved (Table 4). Most likely, this is due to the hrHPV
viral load which was previously observed to be higher in
younger women [26]. This is supported by the fact that
Cp values generated by cobas were lowest in the samples
found hrHPV positive in 3 out of 3 assays followed by 2
out of 3 assays and single positives (Fig. 4). Also, a cor-
relation was observed between severity of cytology and
inter-assay agreement, with an increasing agreement in
the more severe abnormalities (Table 4). The DNA as-
says (HC2 and cobas) show a better concordance than
the Aptima mRNA assay. This is also indicated by the
lower ĸ-coefficient for the mRNA assay vs. the DNA as-
says. In theory, this could be due to decreased stability
of mRNA in archival samples in comparison to DNA as
a target molecule. However, it is more likely the cause of
differences in assay specificity that may be higher in
mRNA based detection, which can subsequently yield
benefits on a population based screening system [27]. In
the Horizon study, inter-assay agreement was slightly
lower with 37.6% (to be able to compare results, samples
only hrHPV positive in CLART were excluded) [24].
Moreover, in the Horizon study, hrHPV detection by
cobas generated a relatively high number (30.6%) of
hrHPV positives only found by cobas (corrected for sam-
ples that were only hrHPV positive in the CLART assay).
Although not fully elucidating this observation, there
might be an effect of the media used, being SurePath in
the Horizon study whereas PreservCyt was used in our
study [9, 10, 17, 24]. Interestingly, this relatively large
difference between HC2 and cobas was not observed in
a recent study, where comparison of these hrHPV tests
in women with ASC-US (atypical squamous cells of
unknown significance) did not yield significant differ-
ences [28]. This observation might be influenced by the
fact that the recent study utilized samples from a triage
population. Given the higher hrHPV prevalence and
possibly higher viral load in a triage population, one may
expect an increased inter-assay agreement.
Comparing the hrHPV genotyping results of cobas and
Aptima could only be partly done due to the difference
in typing assay setup with hrHPV typing of 16, 18 and
“other” by cobas and 16 and 18/45 by Aptima. However,
hrHPV 16 prevalence was similar with cobas as with
Aptima. Moreover, prevalences of hrHPV 16, 18 and
“other” found in our study were similar to those found
by cobas in the Horizon study [10].
It is of particular interest from a clinical perspective,
which of the hrHPV positives found in our study (i.e.
certain discrepant samples) are most representative for
developing CIN and are therefore of clinical relevance.
However, due to the retrospective and anonymous
nature of this study no link could be made with develop-
ment of CIN at this stage. Future investigations are
being initiated on the linkage of the anonymised hrHPV
data with follow up data from the pathology registry
database to enable the investigation of clinical relevance
of concordant and discrepant hrHPV positive samples in
the DuSC study.
Conclusions
In conclusion, our data strongly suggest a higher
hrHPV prevalence of approximately 8% in the Dutch
cervical cancer screening population than the hrHPV
prevalence of 4–5% that was generally used up to
now. This higher prevalence was determined inde-
pendently of the hrHPV assay used. The complete
automated solutions evaluated will greatly facilitate
the implementation of primary hrHPV testing in
cervival cancer screening.
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